Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen's Q4 financials show mixed results, as strong key product sales are offset by margin erosion and slowing growth. See ...

Amgen Touts Broad Portfolio Momentum, MariTide Milestones and Repatha Access Push at TD ...

Amgen (NASDAQ:AMGN) executives highlighted broad-based commercial momentum, a focus on long-term growth drivers, and several ...

Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsKave Niksefat - Senior Vice President of ...

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA ...

Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue ...

Absci Corporation: Absci Strengthens Clinical Leadership with Appointment of Ransi ...

Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue ...

默沙东集团在TD Cowen大会上展示战略性投资组合转型

2026年3月3日星期二,默沙东集团(NYSE:MRK)在TD Cowen第46届年度医疗保健大会上发表演讲,公布了其战略举措,以缓解其重磅药物KEYTRUDA失去专利独占权后预期的收入影响。该公司强调其专注于创新、多元化和战略性业务发展,同时承认未来面临的挑战和机遇。 MK-3000针对对抗VEGF疗法无反应的糖尿病性黄斑水肿和新生血管性AMD患者。 用于HIV的Islatravir/Lenac ...

安进在TD Cowen会议上:战略增长与挑战并存

2026年3月2日星期一,安进公司 (NASDAQ:AMGN)在TD Cowen第46届年度医疗保健会议上进行了展示。该公司强调了其2025年的强劲表现,主要得益于关键产品的强劲增长,同时也提到了2026年可能面临的挑战,包括市场动态和竞争压力。